1018978-85-2

Basic information

• Product Name: (S)-6-FLUORO-CHROMAN-4-YLAMINE
• Synonyms: (S)-6-FLUOROCHROMAN-4-AMINE;(S)-6-FLUORO-CHROMAN-4-YLAMINE;(4S)-6-Fluoro-3,4-dihydro-2H-1-benzopyran-4-amine;(S)-6-FLUOROCHROMAN-4-AMINE-HCL;(S)-6-fluoro-3,4-dihydro-2H-chromen-4-amine
• CAS NO: 1018978-85-2
• Molecular Formula: C9H10FNO
• Molecular Weight: 167.18
• Mol File: 1018978-85-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 229.76 °C at 760 mmHg
• Flash Point: 92.756 °C
• Appearance: /
• Density: 1.202 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 9.12±0.20(Predicted)
• CAS DataBase Reference: (S)-6-FLUORO-CHROMAN-4-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-6-FLUORO-CHROMAN-4-YLAMINE(1018978-85-2)
• EPA Substance Registry System: (S)-6-FLUORO-CHROMAN-4-YLAMINE(1018978-85-2)

Safety Data

• Hazardous Substances Data: 1018978-85-2(Hazardous Substances Data)

Usage

General Description

(S)-6-Fluoro-chroman-4-ylamine, also known as L-741,626, is a chemical compound that belongs to the class of fluoro substituted chromanes. It is a selective and potent antagonist for the GABAA receptor, specifically targeting the α5 subtype of this receptor. (S)-6-FLUORO-CHROMAN-4-YLAMINE has shown promise in preclinical studies for its potential use in treating cognitive deficits associated with conditions such as Alzheimer's disease and schizophrenia. Its mechanism of action involves modulating GABAergic signaling in the brain, which has implications for memory and learning. Its unique selectivity for the α5 subtype of the GABAA receptor makes it a valuable tool for studying the role of this receptor in cognitive function and for developing potential therapies for cognitive disorders.

Upstream product

• 199587-86-5 C₉H₈FNO₂ 
• 890839-05-1 6-fluoro-chroman-4-one O-methyl-oxime 
• 66892-34-0 6-fluoro-4-chromanone 

Downstream Products

• 1219624-70-0 N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-2-(2-oxo-3,3-diphenylpiperidin-1-yl)acetamide 

Relevant articles and documents

Selective Heteroaryl N-Oxidation of Amine-Containing Molecules

The first examples of nonenzymatic N-oxidation of heteroarenes in the presence of amines are reported. Pyridine, quinoline, and isoquinoline N-oxides are selectively formed in the presence of more reactive aliphatic and alicyclic amines by use of an in situ protonation strategy and an iminium salt organocatalyst. Application to late-stage functionalization that mimics phase 1 metabolism of small-molecule drugs is also demonstrated.

2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors

A novel class of Janus tyrosine kinase 3 (JAK3) inhibitors based on a 2-benzimidazoylpurinone core structure is described. Through substitution of the benzimidazoyl moiety and optimization of the N-9 substituent of the purinone, compound 24 was identified incorporating a chroman-based functional group. Compound 24 shows excellent kinase activity, good oral bioavailability and demonstrates efficacy in an acute mechanistic mouse model through inhibition of interleukin-2 (IL-2) induced interferon-γ (INF-γ) production.

7-Substituted Purine Derivatives for Immunosuppression

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula III: